A multi-center, phase 2, open label study of safety and efficacy of oral recombinant human lactoferrin (rhLF) monotherapy in patients with advanced renal cell carcinoma (RCC), who have failed at least one regimen of systemic therapy for RCC

Trial Profile

A multi-center, phase 2, open label study of safety and efficacy of oral recombinant human lactoferrin (rhLF) monotherapy in patients with advanced renal cell carcinoma (RCC), who have failed at least one regimen of systemic therapy for RCC

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2008

At a glance

  • Drugs Recombinant lactoferrin (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Apr 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top